The impact of US President Donald Trump’s 100% “tariff bomb” on the pharmaceutical sector is beginning to be visible. American companies are leaving the country and going abroad, which can directly benefit India. In fact, Eli Lilly, one of America’s largest pharmaceutical companies, announced on Monday that it is investing $ 1 billion (about Rs 8,800 crore) in India.
This investment will be made in new manufacturing units and quality facilities over the next few years. This step of the company has come at a time when Trump is preparing to drop a tariff bomb (Trump Tariff on Pharma India) on the pharmaceutical sector. In such a situation, Eli Lilly’s coming to India can prove to be a big boost to the “Make in India” campaign.
What medicines does the company manufacture, including cancer medicines?
According to Eli Lilly, this investment will strengthen contract manufacturing and help bring medicines for obesity, diabetes, Alzheimer’s, cancer and autoimmune diseases to patients around the world. This investment is being considered an important step towards establishing a new global identity for India’s healthcare sector.
47,000 people are employed in this 140 year old company.
Eli Lilly is one of the largest companies in the United States and ranks among the top five largest companies. Its market capitalization is more than $ 795 billion or approximately Rs 70 lakh crore. This 140 year old company has offices in 18 countries and provides medicines to about 125 countries. The company employs approximately 47,000 employees.
The company is impressed by Indian talent and strong infrastructure
Eli Lilly said its decision to invest in India reflects its confidence in the country’s skilled talent, strong infrastructure and the government’s business-friendly policies. The company wants to make India a major hub of its global healthcare network.
Nivriti Rai, CEO of Invest India, said, “Eli Lilly’s investment reflects their confidence in India’s potential and policy stability. This will not only strengthen healthcare but will also accelerate manufacturing in the country.”
Pharmaceutical company to set up manufacturing unit in Hyderabad
The company said it will set up a new manufacturing and quality center in Hyderabad. This center will oversee Eli Lilly’s contract manufacturing network across India and provide advanced technology facilities.
Telangana Chief Minister Revanth Reddy said, “Eli Lilly’s expansion shows that Hyderabad has become a hub of global healthcare innovation. The company recently launched an innovation center here, and now a new manufacturing center is also coming up.” The company said it will immediately begin recruitment for positions such as engineers, chemists, analytical scientists, quality control and management. Patrick Johnson, Chairman of Eli Lilly International, said, “This investment will make India an important part of our global network. We are confident that India will become a new hub of healthcare manufacturing.” The increasing investment in India by American companies amid Trump’s policies clearly indicates that the world is now looking at India as a ‘Pharma Hub’.
